Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and ...
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor ...
News-Medical.Net on MSN
DLL3 on circulating tumor cells predicts tarlatamab success in lung cancer
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor ...
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announces that Columbia University Medical ...
Ultrasensitive detection of circulating tumor DNA can improve clinical outcomes in aggressive B-cell lymphomas by identifying measurable residual disease. Defining remission is challenging due to ...
Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback